- Home
- NLOP vs URGN Comparison
NLOP vs URGN Comparison
Compare NLOP & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLOP
- URGN
- Stock Information
- Founded
- NLOP 2022
- URGN 2004
- Country
- NLOP United States
- URGN United States
- Employees
- NLOP N/A
- URGN N/A
- Industry
- NLOP
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- NLOP
- URGN Health Care
- Exchange
- NLOP Nasdaq
- URGN Nasdaq
- Market Cap
- NLOP 452.1M
- URGN 465.9M
- IPO Year
- NLOP N/A
- URGN 2017
- Fundamental
- Price
- NLOP $31.59
- URGN $11.20
- Analyst Decision
- NLOP Strong Buy
- URGN Strong Buy
- Analyst Count
- NLOP 1
- URGN 6
- Target Price
- NLOP $46.00
- URGN $40.75
- AVG Volume (30 Days)
- NLOP 96.3K
- URGN 408.1K
- Earning Date
- NLOP 01-01-0001
- URGN 03-10-2025
- Dividend Yield
- NLOP 1.08%
- URGN N/A
- EPS Growth
- NLOP N/A
- URGN N/A
- EPS
- NLOP N/A
- URGN N/A
- Revenue
- NLOP $142,247,000.00
- URGN $90,398,000.00
- Revenue This Year
- NLOP N/A
- URGN $43.60
- Revenue Next Year
- NLOP N/A
- URGN $103.77
- P/E Ratio
- NLOP N/A
- URGN N/A
- Revenue Growth
- NLOP N/A
- URGN 9.29
- 52 Week Low
- NLOP $22.16
- URGN $9.03
- 52 Week High
- NLOP $34.38
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- NLOP 54.25
- URGN 52.93
- Support Level
- NLOP $30.89
- URGN $11.12
- Resistance Level
- NLOP $31.74
- URGN $11.91
- Average True Range (ATR)
- NLOP 0.56
- URGN 0.59
- MACD
- NLOP 0.12
- URGN -0.07
- Stochastic Oscillator
- NLOP 87.97
- URGN 37.10
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.